NEARLY EVERYONE ≥50 YEARS OLD IS AT RISK OF SHINGLES , NO MATTER HOW HEALTHY THEY MAY FEEL * 1-4
NEARLY EVERYONE ≥50 YEARS OLD IS AT RISK OF SHINGLES , NO MATTER HOW HEALTHY THEY MAY FEEL * 1-4
MAKE SHINGLES DISCUSSIONS A PRIORITY FOR YOUR PATIENTS
* Immunodeficiency caused by medical conditions or immunosuppressive medications may also increase the risk of shingles . 2 , 4
PBS Information : SHINGRIX is listed on the National Immunisation Program ( NIP ) for Aboriginal and Torres Strait Islander adults aged ≥50 years , for all individuals aged ≥65 years and for adults aged ≥18 years with some immunocompromising medical risk conditions . Refer to NIP schedule or your State or Territory Health department .
Please review full Product Information before prescribing . Product Information can be accessed at www . gsk . com . au / shingrix or by scanning the QR code .
Scan to discover more at gskpro . com
This medicinal product is subject to additional monitoring in Australia . This will allow quick identification of new safety information . Healthcare professionals are asked to report any suspected adverse events at www . tga . gov . au / reporting-problems .
References : 1 . Weinberg A , et al . J Infect Dis . 2010 ; 201 ( 7 ): 1024-30 . 2 . Center for Disease Control and Prevention ( CDC ). MMWR . 2008 June ; 57 ( RR-5 ): 1-30 . 3 . National Centre for Immunisation Research and Surveillance ( NCIRS ). Zoster vaccines ( Shingrix ® [ RZV ] and Zostavax ® [ ZVL ]) – FAQs . Available at : ncirs . org . au / zoster / zostervaccines-shingrixr-rzv-and-zostavaxr-zvl-faqs ( accessed January 2024 ). 4 . Australian Technical Advisory Group on Immunisation ( ATAGI ). Australian Immunisation Handbook , Australian Government Department of Health and Aged Care , Canberra , 2022 . Available at : immunisationhandbook . health . gov . au ( accessed January 2024 ).
For information on GSK products or to report an adverse event involving a GSK product , please contact GSK Medical Information on 1800 033 109 . Trade marks are owned by or licensed to the GSK group of companies . © 2024 GSK group of companies or its licensor . GlaxoSmithKline Australia Pty Ltd . Melbourne , VIC . ABN 47 100 162 481 . PM-AU-SGX-JRNA-240002 . Date of approval : February 2024 .